-

07:17:09 AM

Latest SCYX Stock Market News

SCYX - Scynexis Inc

09/22/21 8:30 AM

Nasdaq : SCYX

SCYNEXIS Announces U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years

First and only oral non-azole treatment option approved for vaginal yeast infections is now available in pharmacies including cloud-based pharmacy New treatment is fungicidal against Candida species, disrupting the fungal cell wall and killing the fungi causing the infection, rather than only

RHEA-AI

neutral

09/13/21 8:30 AM

Nasdaq : SCYX

clinical trial

SCYNEXIS Announces Hansoh Pharma’s Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative

RHEA-AI

very positive

09/08/21 8:30 AM

Nasdaq : SCYX

conferences

SCYNEXIS to Participate in Upcoming Investor Conferences

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Company will participate in the following virtual

RHEA-AI

neutral

08/16/21 8:00 AM

Nasdaq : SCYX

earnings

SCYNEXIS Reports Second Quarter 2021 Financial Results and Provides Corporate Update

BREXAFEMME ® (ibrexafungerp tablets), the first novel antifungal class drug approved by the U.S. Food and Drug Administration (FDA) in more than 20 years, qualifies for 10 years of regulatory exclusivity and has 14 years of U.S. patent protection U.S. commercial launch of BREXAFEMME began in

RHEA-AI

positive

08/02/21 5:00 PM

Nasdaq : SCYX

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced grants of stock options to five new employees to purchase an

RHEA-AI

neutral

07/29/21 8:00 AM

Nasdaq : SCYX

clinical trial

SCYNEXIS Announces Two Oral Presentations on Pooled Data from the BREXAFEMME (Ibrexafungerp tablets) Phase 3 VANISH Program Demonstrating Consistent Efficacy in the Treatment for Vaginal Yeast Infections at the IDSOG 2021 Virtual Annual Meeting

The pooled data from two Phase 3 studies (VANISH-303 and VANISH-306) of one-day oral ibrexafungerp reflect a population that overwhelmingly had severe yeast infections, a condition typically treated with multiple doses of oral fluconazole Ibrexafungerp demonstrated consistent efficacy in important

RHEA-AI

neutral

07/12/21 8:00 AM

Nasdaq : SCYX

SCYNEXIS Announces Three Oral Presentations of Ibrexafungerp Demonstrating Clinical and In Vitro Activity Against Candida Species at the 31st ECCMID

FURI and CARES presentations show ibrexafungerp’s strong clinical response in difficult-to-treat and refractory fungal infections in the hospital setting including Candida auris In vitro data demonstrates ibrexafungerp’s broad activity against 967 clinical Candida isolates from patients in Denmark,

RHEA-AI

neutral

07/07/21 8:30 AM

Nasdaq : SCYX

conferences

SCYNEXIS to Present at Ladenburg Thalmann’s Virtual 2021 Healthcare Conference

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Eric Francois, Chief Financial Officer, will present at

RHEA-AI

neutral

07/02/21 4:01 PM

Nasdaq : SCYX

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced grants of stock options to four new employees to purchase an

RHEA-AI

neutral

06/23/21 8:30 AM

Nasdaq : SCYX

conferences

SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)

BREXAFEMME, a one-day, novel, oral treatment for vaginal yeast infection, is the first FDA-approved indication of the ibrexafungerp antifungal development pipeline and the first approved drug from a novel antifungal class in over 20 years Commercial launch update call is scheduled for Tuesday, June

RHEA-AI

very positive

SCYX Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.scynexis.com
Security nameScynexis Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees38
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address1 Evertrust Plz Fl 13
StateNew Jersey
CityJersey City
Zip07302-3051
CountryUS
Phone12018845485

SCYX Description:

SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Its lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class. It is currently under review by the FDA as a treatment for vaginal yeast infections and in late-stage development for multiple life-threatening fungal infections in hospitalized patients.